Loading...
Clinuvel Pharmaceuticals Limited
CLVLY•PNK
Healthcare
Biotechnology
$8.44
$0.00(0.00%)
U.S. Market opens in NaNh NaNmClinuvel Pharmaceuticals Limited (CLVLY) AI-Powered Stock Analysis
See how Clinuvel Pharmaceuticals Limited scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerClinuvel Pharmaceuticals Limited (CLVLY) Stock Overall Grade
Clinuvel Pharmaceuticals Limited’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Clinuvel Pharmaceuticals Limited's overall stock rating.
Forecast
C+Score
54/100Financial Growth
AScore
85/100Fundamental Growth
BScore
67/100Key Ratios
A+Score
91/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
C+Score
50/100Clinuvel Pharmaceuticals Limited (CLVLY) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 54/100 (C+), reflecting weak confidence in its potential. Financial Growth (85/100, A) and Fundamental Growth (67/100, B) highlight its stability, while Key Ratios (91/100, A+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Clinuvel Pharmaceuticals Limited stock grade, including financials, comparisons, and forecasts.